Michael Mccallister Buys 3,000 Shares of Zoetis (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) Director Michael Mccallister acquired 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Zoetis Price Performance

Shares of Zoetis stock traded up $0.25 during trading on Tuesday, hitting $76.92. 18,424,772 shares of the company were exchanged, compared to its average volume of 6,276,606. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a fifty-two week low of $75.11 and a fifty-two week high of $172.23. The stock has a market capitalization of $32.25 billion, a price-to-earnings ratio of 12.76, a P/E/G ratio of 1.25 and a beta of 0.87. The firm has a 50 day moving average price of $116.50 and a 200 day moving average price of $122.77.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Stifel Nicolaus set a $105.00 price target on Zoetis in a report on Friday. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $141.25.

Institutional Trading of Zoetis

Institutional investors and hedge funds have recently made changes to their positions in the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the 4th quarter worth $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter worth $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the 3rd quarter worth $31,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth $28,000. Finally, Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the 4th quarter worth $30,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.